Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05055921
Other study ID # CL007 (US)
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date February 28, 2022
Est. completion date October 1, 2022

Study information

Verified date October 2022
Source Cardialen, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Assess the clinical safety and feasibility of MultiPulse Therapy (MPT) electrical stimulation waveform sequence in terminating paroxysmal and persistent atrial fibrillation.


Description:

A prospective non-randomized feasibility study involving acute testing of MPT in subjects with paroxysmal and persistent AF during clinically indicated atrial fibrillation catheter ablation procedure. Subjects will be split into 2 cohorts depending on status at time of procedure. 1. In Atrial Fibrillation at time of procedure (Clinical AF) 2. In Normal Sinus Rhythm at time of procedure Subjects will be evaluated at the visits for the Clinically-Indicated Procedure per standard of care. A single follow-up at up to 30 days post-procedure is required to assess subjects for adverse events.


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date October 1, 2022
Est. primary completion date October 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Male or female between 18 and 80 years of age 2. Willing and able to comply with the study protocol, provide a written informed consent 3. Currently indicated for atrial catheter ablation due to paroxysmal or early persistent atrial fibrillation 4. Current treatment and compliance with standard anticoagulation regimen, including uninterrupted OAC, with acceptable coagulation status, as determined by the Principal Investigator Exclusion Criteria: The subject must not meet any of the following exclusion criteria: 1. Life expectancy of 1 year or less 2. AF due to reversible causes (e.g., hyperthyroidism, valve disease) 3. History of DC Cardioversion which failed to convert to AF to Normal Sinus Rhythm 4. Currently in AF for more than 3 months continuously 5. Chronic, long-standing persistent, or permanent atrial fibrillation 6. Allergy or contraindication to anticoagulation therapy 7. Presence of intracardiac thrombus (confirmed with TEE or ICE) 8. Existing Left Atrial Appendage closure device 9. Severely Dilated Left Atrium >5cm 10. LVEF<35% 11. NYHA Class III or IV heart failure at the time of enrollment 12. History of embolic stroke, Transient Ischemic Attack (TIA) or other thromboembolic event within the preceding 3 months. 13. Known hyper-coagulable state that increases risk of thrombus 14. History of myocardial infarction or coronary revascularization within the preceding 3 months. 15. History of sustained ventricular arrhythmia or cardiac arrest 16. Presence of chronically implanted lead in the CS 17. Presence of ventricular assist device, including intra-aortic balloon pump 18. Documented bradycardia (<40 BPM) at the time of the study 19. Morbid obesity: BMI>39 kg/m2 20. Presence of any prosthetic cardiac valve 21. History of significant tricuspid valvular disease requiring surgery 22. Moderate to severe mitral valve regurgitation (>40% regurgitation fraction) 23. Cognitive or mental health status that would interfere with study participation and proper informed consent 24. Cardiovascular anatomical defects that would complicate placement of the stimulation leads required by the protocol, including congenital heart disease and cardiac vein anomalies per the Investigator's discretion 25. Pregnancy confirmed by test within 7 days of procedure. 26. Inability to pass catheters to heart due to vascular limitations 27. Cardiovascular surgery or intervention within 1 month prior to enrollment or planned for up to 1 month after enrollment (other than the planned treatment procedure) 28. Active endocarditis 29. Any other medical condition which may affect the outcome of this study or safety of the subject as determined by the investigator 30. History of hemodynamic compromise due to valvular heart disease 31. Unstable CAD as determined by the investigator 32. Severe proximal three-vessel or left main coronary artery disease without revascularization as determined by the investigator 33. History of Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia, Congenital Heart Anomaly, Cardiac Amyloidosis or Cardiac Sarcoidosis

Study Design


Intervention

Device:
Multi Pulse Therapy as delivered from the Cardialen External Stimulation System
The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen MultiPulse Therapy (MPT). The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software. Other Names: Unpinning Termination Therapy Multi-stage therapy Multi-stage electrotherapy MultiPulse Therapy

Locations

Country Name City State
United States The Ohio State University Columbus Ohio
United States Minneapolis Veterans Administration Hospital Minneapolis Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Cardialen, Inc. Iqvia Pty Ltd

Country where clinical trial is conducted

United States, 

References & Publications (4)

Ambrosi CM, Ripplinger CM, Efimov IR, Fedorov VV. Termination of sustained atrial flutter and fibrillation using low-voltage multiple-shock therapy. Heart Rhythm. 2011 Jan;8(1):101-8. doi: 10.1016/j.hrthm.2010.10.018. Epub 2010 Oct 19. — View Citation

Efimov I, Ripplinger CM. Virtual electrode hypothesis of defibrillation. Heart Rhythm. 2006 Sep;3(9):1100-2. Epub 2006 Mar 10. — View Citation

Janardhan AH, Gutbrod SR, Li W, Lang D, Schuessler RB, Efimov IR. Multistage electrotherapy delivered through chronically-implanted leads terminates atrial fibrillation with lower energy than a single biphasic shock. J Am Coll Cardiol. 2014 Jan 7-14;63(1):40-8. doi: 10.1016/j.jacc.2013.07.098. Epub 2013 Sep 26. — View Citation

Li W, Janardhan AH, Fedorov VV, Sha Q, Schuessler RB, Efimov IR. Low-energy multistage atrial defibrillation therapy terminates atrial fibrillation with less energy than a single shock. Circ Arrhythm Electrophysiol. 2011 Dec;4(6):917-25. doi: 10.1161/CIRCEP.111.965830. Epub 2011 Oct 6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The safety of MPT for the treatment of atrial fibrillation in subjects Reported Adverse Events following MPT delivery Acutely at the time of the study procedure
Primary The safety of MPT for the treatment of atrial fibrillation in subjects Reported Adverse Events following MPT delivery At 30 day post procedure
Primary Enhanced ability of MPT to stop atrial fibrillation Compare voltages at which MPT successfully terminated AF against a previous Cardialen AF study (CL001 / NCT02257112) Acutely following MPT delivery
Primary Ability of MPT to stop atrial fibrillation Determine rate of conversion from AF to NSR Acutely following MPT delivery
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A